A randomised, double-blind, parallel-group trial to assess mercaptopurine versus placebo to prevent or delay recurrence of Crohn’s disease following surgical resection (TOPPIC)
Author
Satsangi, J.
Kennedy, Nicholas A.
Mowat, C.
Arnott, I.
Keerie, C.
Lewis, S.
Ennis, H.
Date
2017-09Journal
Efficacy and Mechanism EvaluationType
Technical reportPublisher
NIHRMetadata
Show full item recordAbstract
Crohn’s disease (CD) is a chronic, relapsing, inflammatory bowel disease. Up to 65% of patients with CD require an operation to control the disease within 10 years. Both endoscopic and clinical recurrence is common within 2 years of operation, with re-operation rates cumulating at 5% of patients per year.